Taxifolin inhibited signal transduction of SOS1 by blocking the interaction between SOS1 and Grb2, demonstrating that taxifolin could be effective in combating SOS1-driven tumor progression, demonstrating the potential utility of the compound as a treatment for patients with AA-type breast cancer (Xing et al., 2021). This evidence concerns the gene SOS1 and neoplasm.